|
Mar 6
|
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Feb 2
|
Down -12.91% in 4 Weeks, Here's Why Guardant Health (GH) Looks Ripe for a Turnaround
|
|
Feb 1
|
Guardant Health to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024
|
|
Feb 1
|
Guardant Health (GH) Loses -13.59% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
|
|
Jan 17
|
Guardant Health to present data at ASCO GI supporting use of liquid biopsy to predict colon cancer recurrence
|
|
Dec 21
|
Guardant Health Announces $90.7 Million Registered Direct Offering with Baillie Gifford
|
|
Dec 20
|
Blood-Based Colorectal Cancer CRC Screening Market Likely to Benefit From FDA's Panel Surprise Advisory Possibility: Analyst
|
|
Dec 20
|
Guardant Health to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
|
|
Dec 19
|
Guardant Health Announces Tentative Date of FDA Advisory Panel Review of Shield™ Blood Test
|
|
Dec 5
|
Insider Sell: CIO Kumud Kalia Divests 5,800 Shares of Guardant Health Inc
|
|
Dec 4
|
Cancer Research UK and Guardant Health Launch Collaboration to Advance Cancer Research and Clinical Development Activities
|
|
Nov 30
|
Guardant Health to present data at San Antonio Breast Cancer Symposium demonstrating utility of liquid biopsy in biomarker identification, therapy selection and residual disease detection
|
|
Sep 9
|
Guardant Health (GH) Stock: A Hidden Value Trap? Unpacking the Risks and Rewards
|
|
Sep 6
|
Guardant Health Receives Coverage for Guardant Reveal™ from Geisinger Health Plan
|
|
Jun 23
|
Guardant Health Stock Reaches 80-Plus Relative Strength Rating Benchmark
|
|
Apr 27
|
Guardant Health to Participate in the BofA Securities 2023 Healthcare Conference
|
|
Apr 26
|
Down -6.66% in 4 Weeks, Here's Why You Should You Buy the Dip in Guardant Health (GH)
|
|
Apr 25
|
Guardant Health and Parker Institute for Cancer Immunotherapy (PICI) launch research collaboration to study connection between cancer biomarkers and immunotherapy treatment response
|